About OrthoIQ
OrthoIQ is developing IQ Impact, a powered autoimpactor for total hip replacement surgery. A sensor inside the tool alerts the surgeon when the implant is fully seated and when the patient's bone fractures. The tool is still in development and is not for sale.
OrthoIQ is based in Cambridge, Massachusetts. Audrey Chen is chief executive officer. She has a mechanical engineering background from MIT and has managed regulated product development at organizations such as NASA and Formlabs. Dr. Phillip Merritt, a founder and chief medical officer, is medical director of the Orthopedic Institute at Adventist Health Glendale. Alan Davidner, a founder and advisor, has started four medtech companies and holds 67 issued patents. The company works with outside development firms and subject matter experts rather than building everything in house.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 20, 2022 | Oct 23, 2026 | $1,080,000of $1.4M target | 25 | $43,200 | Options, Securities on exercise, Convertible DebtRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed OrthoIQ
OrthoIQ is developing IQ Impact, a powered impactor that senses when a hip implant is fully seated. Today surgeons judge seating by feel and sound, and IQ Impact is designed to add objective data to those cues. The tool is in bench testing and is not yet for sale.
The problem it targets
Surgeons drive a hip implant into bone with hammer strikes. They stop when the feel and sound of the strikes say it is seated. These cues depend on experience and give no objective measure. An under-seated implant may fail to fix firmly and can loosen over time. Over-impaction can fracture the bone around the implant. According to the American Joint Replacement Registry's 2025 report, 45.5% of hip revisions come from instability, periprosthetic fracture or aseptic loosening. Heo and colleagues, in The Journal of Arthroplasty in 2026, put annual U.S. hospital charges for instability-related hip revisions at $294 million. They project $533 million by 2035.
What the product does
IQ Impact replaces the manual mallet with controlled, repeatable strikes. A sensor inside the tool sends an update every few seconds. The update tells the surgeon to keep going while the implant is still seating and to stop once it is fully seated. A fracture triggers an immediate alert. OrthoIQ's stated aim is to add to a surgeon's experience, not replace it. In OrthoIQ's own comparison with the DePuy Synthes autoimpactor, IQ Impact has half the weight and costs $30,000 against $55,000.
Progress so far
Concept and design are complete, and a prototype has been built. Bench testing and sensing validation are in progress. OrthoIQ expects to freeze the design in 2027 and finish validation and FDA approval in 2028. It expects a commercial launch in 2029. The company works with ISO 13485 compliant development firms and brings in subject matter experts for each project. A U.S. patent for orthopedic surgery systems that impact implants in bone was issued to OrthoIQ on August 26, 2025, according to US Fed News.
We wrote this summary from public statements by OrthoIQ and its investors. It is not investment advice.
OrthoIQ in the News
Leadership Team
Executive officers and directors listed on OrthoIQ's Form D filed Oct 23, 2026.
